{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HIV+Seronegative&page=2",
    "query": {
      "condition": "HIV Seronegative",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HIV+Seronegative&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-26T19:23:52.261Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01575405",
      "title": "A Study to Compare Three Different Formulations of Tenofovir 1% Gel When Administered Rectally",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Prevention"
      ],
      "interventions": [
        {
          "name": "Rectal formulation (RF) of tenofovir 1% gel",
          "type": "DRUG"
        },
        {
          "name": "Vaginal formulations (original VF and reduced vaginal glycerin formulation RGVF) of tenofovir 1% gel",
          "type": "DRUG"
        },
        {
          "name": "Universal HEC Placebo Gel Formulation",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ian McGowan",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2013-03",
      "completion_date": "2013-11",
      "has_results": false,
      "last_update_posted_date": "2013-11-07",
      "last_synced_at": "2026-06-26T19:23:52.261Z",
      "location_count": 2,
      "location_summary": "Los Angeles, California • Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01575405"
    },
    {
      "nct_id": "NCT00000798",
      "title": "A Phase I Safety and Immunogenicity Trial of UBI Microparticulate Monovalent HIV-1 MN Peptide Immunogen in HIV-1 Seronegative Human Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "HIV-1 Peptide Vaccine, Microparticulate Monovalent",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 32,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-06-26T19:23:52.261Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland • Rochester, New York",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00000798"
    },
    {
      "nct_id": "NCT00005762",
      "title": "Drug Interactions of Amprenavir and Efavirenz, in Combination With a Second Protease Inhibitor, in HIV-Negative Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Indinavir sulfate",
          "type": "DRUG"
        },
        {
          "name": "Ritonavir",
          "type": "DRUG"
        },
        {
          "name": "Amprenavir",
          "type": "DRUG"
        },
        {
          "name": "Nelfinavir mesylate",
          "type": "DRUG"
        },
        {
          "name": "Efavirenz",
          "type": "DRUG"
        },
        {
          "name": "Saquinavir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 90,
      "start_date": "2001-03",
      "completion_date": "2004-05",
      "has_results": false,
      "last_update_posted_date": "2021-11-01",
      "last_synced_at": "2026-06-26T19:23:52.261Z",
      "location_count": 8,
      "location_summary": "Palo Alto, California • Aurora, Colorado • Honolulu, Hawaii + 5 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Honolulu",
          "state": "Hawaii"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00005762"
    },
    {
      "nct_id": "NCT02033109",
      "title": "Safety, Pharmacokinetics and Acceptability of PC-1005 for Vaginal Use",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV"
      ],
      "interventions": [
        {
          "name": "PC-1005",
          "type": "DRUG"
        },
        {
          "name": "HEC gel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Population Council",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "49 Years",
        "sex": "FEMALE",
        "summary": "19 Years to 49 Years · Female only"
      },
      "enrollment_count": 35,
      "start_date": "2014-05",
      "completion_date": "2015-06",
      "has_results": false,
      "last_update_posted_date": "2017-08-15",
      "last_synced_at": "2026-06-26T19:23:52.261Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02033109"
    },
    {
      "nct_id": "NCT00001053",
      "title": "A Phase I Safety and Immunogenicity Study of HIV p17/p24:Ty-VLP in HIV-1 Seronegative Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "HIV p17/p24:Ty-VLP",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Aluminum hydroxide",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 36,
      "start_date": null,
      "completion_date": "1996-03",
      "has_results": false,
      "last_update_posted_date": "2021-11-04",
      "last_synced_at": "2026-06-26T19:23:52.261Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00001053"
    },
    {
      "nct_id": "NCT00013572",
      "title": "HIV Candidate Vaccine, ALVAC-HIV-1, Administration in HIV-Negative Adults",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections",
        "HIV Seronegativity"
      ],
      "interventions": [
        {
          "name": "ALVAC-HIV MN120TMG (vCP205)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Walter Reed Army Institute of Research (WRAIR)",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 36,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-06-26T19:23:52.261Z",
      "location_count": 1,
      "location_summary": "Rockville, Maryland",
      "locations": [
        {
          "city": "Rockville",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00013572"
    },
    {
      "nct_id": "NCT00000845",
      "title": "A Phase I Safety and Immunogenicity Trial of UBI HIV Lipopeptide Vaccine Component P3C541b in HIV-1 Seronegative Human Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "P3C541b Lipopeptide",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 30,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-06-26T19:23:52.261Z",
      "location_count": 3,
      "location_summary": "Baltimore, Maryland • Nashville, Tennessee • Seattle, Washington",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00000845"
    },
    {
      "nct_id": "NCT03044379",
      "title": "Dapivirine Gel Rectal Safety and PK Study",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV 1 Infection"
      ],
      "interventions": [
        {
          "name": "Dapivirine gel (0.05%)",
          "type": "DRUG"
        },
        {
          "name": "Universal HEC placebo gel",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "International Partnership for Microbicides, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 0,
      "start_date": "2015-09-29",
      "completion_date": "2017-11",
      "has_results": false,
      "last_update_posted_date": "2017-02-08",
      "last_synced_at": "2026-06-26T19:23:52.261Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03044379"
    },
    {
      "nct_id": "NCT03408899",
      "title": "Evaluating the Safety and Pharmacokinetics of PC-1005 Administered Rectally to HIV-1 Seronegative Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "PC-1005 gel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2018-06-19",
      "completion_date": "2019-04-19",
      "has_results": true,
      "last_update_posted_date": "2023-04-14",
      "last_synced_at": "2026-06-26T19:23:52.261Z",
      "location_count": 2,
      "location_summary": "Birmingham, Alabama • Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03408899"
    },
    {
      "nct_id": "NCT00002204",
      "title": "A Phase I, Observer-Blind, Placebo-Controlled Study of the Chiron Vaccine HIV p24/MF59 Administered to Healthy HIV-Seronegative Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections",
        "HIV Seronegativity"
      ],
      "interventions": [
        {
          "name": "HIV p24/MF59 Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Chiron Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 40,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-06-26T19:23:52.261Z",
      "location_count": 1,
      "location_summary": "Omaha, Nebraska",
      "locations": [
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002204"
    }
  ]
}